NASDAQ:FGEN - FibroGen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$53.45 +0.90 (+1.71 %)
(As of 05/23/2018 01:01 AM ET)
Previous Close$53.45
Today's Range$52.55 - $54.20
52-Week Range$25.35 - $63.00
Volume378,102 shs
Average Volume548,599 shs
Market Capitalization$4.27 billion
P/E Ratio-30.90
Dividend YieldN/A
Beta1.9

About FibroGen (NASDAQ:FGEN)

FibroGen logoFibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200

Debt

Debt-to-Equity Ratio0.19
Current Ratio8.61
Quick Ratio8.61

Price-To-Earnings

Trailing P/E Ratio-30.90
Forward P/E Ratio-33.83
P/E GrowthN/A

Sales & Book Value

Annual Sales$125.67 million
Price / Sales35.52
Cash FlowN/A
Price / CashN/A
Book Value$7.09 per share
Price / Book7.54

Profitability

EPS (Most Recent Fiscal Year)($1.73)
Net Income$-126,200,000.00
Net Margins-102.86%
Return on Equity-27.70%
Return on Assets-16.78%

Miscellaneous

Employees423
Outstanding Shares83,520,000

FibroGen (NASDAQ:FGEN) Frequently Asked Questions

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen (NASDAQ:FGEN) issued its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.01. The biopharmaceutical company earned $42.51 million during the quarter, compared to analyst estimates of $45.37 million. FibroGen had a negative return on equity of 27.70% and a negative net margin of 102.86%. View FibroGen's Earnings History.

When is FibroGen's next earnings date?

FibroGen is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for FibroGen.

What price target have analysts set for FGEN?

7 Wall Street analysts have issued 1 year target prices for FibroGen's shares. Their predictions range from $31.00 to $88.00. On average, they expect FibroGen's share price to reach $66.6667 in the next year. View Analyst Ratings for FibroGen.

What are Wall Street analysts saying about FibroGen stock?

Here are some recent quotes from research analysts about FibroGen stock:
  • 1. Mizuho analysts commented, "We expect to see top-line phase 3 data from Disease (CKD) in 4Q18 and a potential regulatory approval in China is expected by year-end 2018. We upgrade to Buy and maintain our $61 PT as we believe the company is likely to gain the first approval in new generation anemia drugs. If Pamrevlumab reproduces its Phase II results in the planned Phase III trial, we see significant upside." (5/15/2018)
  • 2. According to Zacks Investment Research, "FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. " (5/14/2018)

Who are some of FibroGen's key competitors?

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:
  • Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 64)
  • Mr. Pat Cotroneo, VP of Fin. & CFO (Age 54)
  • Dr. K. Peony Yu M.D., Chief Medical Officer (Age 56)
  • Dr. Barry A. Berkowitz, Founder
  • Dr. Michael J. Martinelli Ph.D., VP of Technical Devel.

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Has FibroGen been receiving favorable news coverage?

News stories about FGEN stock have been trending somewhat positive on Tuesday, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. FibroGen earned a daily sentiment score of 0.15 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.62 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are FibroGen's major shareholders?

FibroGen's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.09%), Farallon Capital Management LLC (2.06%), JPMorgan Chase & Co. (1.16%), Northern Trust Corp (1.00%), Eagle Asset Management Inc. (0.98%) and Lord Abbett & CO. LLC (0.69%). Company insiders that own FibroGen stock include Gerald Lema, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Which institutional investors are selling FibroGen stock?

FGEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Sphera Funds Management LTD., Citigroup Inc., Nexthera Capital LP, Wells Fargo & Company MN, Pinnacle Associates Ltd. and Dimensional Fund Advisors LP. Company insiders that have sold FibroGen company stock in the last year include Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Insider Buying and Selling for FibroGen.

Which institutional investors are buying FibroGen stock?

FGEN stock was acquired by a variety of institutional investors in the last quarter, including PointState Capital LP, Artal Group S.A., UBS Group AG, Amundi Pioneer Asset Management Inc., Lord Abbett & CO. LLC, BNP Paribas Arbitrage SA, Millennium Management LLC and Prudential Financial Inc.. View Insider Buying and Selling for FibroGen.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $53.45.

How big of a company is FibroGen?

FibroGen has a market capitalization of $4.27 billion and generates $125.67 million in revenue each year. The biopharmaceutical company earns $-126,200,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. FibroGen employs 423 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]


MarketBeat Community Rating for FibroGen (FGEN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  311
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

FibroGen (NASDAQ:FGEN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for FibroGen in the last 12 months. Their average twelve-month price target is $66.6667, suggesting that the stock has a possible upside of 24.73%. The high price target for FGEN is $88.00 and the low price target for FGEN is $31.00. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.862.862.88
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $66.6667$66.6667$65.6667$65.6667
Price Target Upside: 24.73% upside44.30% upside21.49% upside21.49% upside

FibroGen (NASDAQ:FGEN) Consensus Price Target History

Price Target History for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018MizuhoUpgradeNeutral ➝ Buy$61.00HighView Rating Details
2/28/2018Leerink SwannReiterated RatingOutperform$80.00 ➝ $88.00HighView Rating Details
9/14/2017Stifel NicolausReiterated RatingBuy$80.00LowView Rating Details
9/12/2017Jefferies GroupReiterated RatingBuy$75.00LowView Rating Details
8/9/2017William BlairReiterated RatingOutperformMediumView Rating Details
8/8/2017CitigroupBoost Price TargetTop Pick$48.00 ➝ $65.00HighView Rating Details
7/21/2017Goldman SachsDowngradeBuy ➝ Neutral$31.00MediumView Rating Details
1/18/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
8/9/2016Credit Suisse GroupReiterated RatingBuy$37.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

FibroGen (NASDAQ:FGEN) Earnings History and Estimates Chart

Earnings by Quarter for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.46)
2019 EPS Consensus Estimate: $1.08
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.52)($0.48)($0.50)
Q2 20183($0.56)($0.50)($0.53)
Q3 20183($0.58)$0.00($0.38)
Q4 20183($0.68)$0.59($0.05)
Q1 20191$2.63$2.63$2.63
Q2 20191($0.79)($0.79)($0.79)
Q3 20191($0.77)($0.77)($0.77)
Q4 20191$0.01$0.01$0.01

FibroGen (NASDAQ FGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.55)N/AView Earnings Details
5/9/2018Q1 2018($0.51)($0.50)$29.07 million$31.90 millionViewN/AView Earnings Details
2/27/2018Q4 2017($0.28)($0.27)$45.37 million$42.51 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.37)($0.50)$41.34 million$27.27 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.47)($0.48)$34.80 million$29.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.63)($0.52)$26.02 million$26.89 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.53)($0.54)$19.29 million$31.91 millionViewListenView Earnings Details
11/8/2016Q3($0.63)($0.38)$24.30 million$30.10 millionViewListenView Earnings Details
8/8/2016Q2$0.36$0.35$80.58 million$89.28 millionViewListenView Earnings Details
5/9/2016Q116($0.56)($0.45)$16.89 million$28.28 millionViewListenView Earnings Details
2/29/2016Q4($0.54)($0.85)$40.44 million$24.44 millionViewListenView Earnings Details
11/12/2015Q3($0.6050)($0.74)$28.74 million$19.54 millionViewListenView Earnings Details
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details
5/12/2015Q115($0.53)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details
3/26/2015Q414($0.90)($0.82)$16.49 million$16.11 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

FibroGen (NASDAQ:FGEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

FibroGen (NASDAQ FGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.96%
Institutional Ownership Percentage: 63.47%
Insider Trading History for FibroGen (NASDAQ:FGEN)
Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ FGEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2018Kalevi KurkijarviDirectorSell4,000$51.83$207,320.00View SEC Filing  
5/17/2018Thomas B NeffCEOSell39,636$51.82$2,053,937.52View SEC Filing  
5/9/2018Jorma RouttiDirectorSell6,000$47.10$282,600.00133,840View SEC Filing  
5/3/2018Thomas B NeffCEOSell39,636$47.04$1,864,477.442,916,493View SEC Filing  
4/19/2018Kalevi KurkijarviDirectorSell4,000$47.69$190,760.0024,000View SEC Filing  
4/18/2018Thomas B NeffCEOSell39,636$48.56$1,924,724.162,933,653View SEC Filing  
4/16/2018K Peony YuInsiderSell7,500$47.81$358,575.00156,233View SEC Filing  
4/9/2018Jorma RouttiDirectorSell6,000$46.59$279,540.00133,840View SEC Filing  
4/5/2018Thomas B NeffCEOSell39,636$45.59$1,807,005.242,950,813View SEC Filing  
3/21/2018Thomas B NeffCEOSell39,636$50.95$2,019,454.202,969,251View SEC Filing  
3/15/2018Pat CotroneoVPSell42,026$52.85$2,221,074.10168,334View SEC Filing  
3/15/2018Roberto Pedro RosenkranzDirectorSell1,000$52.34$52,340.0024,000View SEC Filing  
3/14/2018K Peony YuInsiderSell9,891$53.20$526,201.20128,333View SEC Filing  
3/13/2018Pat CotroneoCFOSell5,932$54.61$323,946.52168,334View SEC Filing  
3/12/2018Thomas F Kearns JrDirectorSell18,000$55.00$990,000.00135,064View SEC Filing  
3/9/2018Rory B RiggsDirectorSell22,905$55.75$1,276,953.75411,295View SEC Filing  
3/8/2018Pat CotroneoVPSell1,894$53.12$100,609.28176,160View SEC Filing  
3/8/2018Thomas B NeffCEOSell39,636$53.14$2,106,257.042,907,425View SEC Filing  
2/23/2018Thomas B NeffCEOSell39,636$56.66$2,245,775.762,955,614View SEC Filing  
2/16/2018Pat CotroneoVPSell49,500$55.96$2,770,020.00207,392View SEC Filing  
2/15/2018Kalevi KurkijarviDirectorSell6,000$55.69$334,140.0026,000View SEC Filing  
2/8/2018K Peony YuInsiderSell7,500$53.97$404,775.00144,986View SEC Filing  
1/30/2018Thomas B NeffCEOSell38,636$61.40$2,372,250.402,958,105View SEC Filing  
1/29/2018K Peony YuInsiderSell10,000$62.00$620,000.00152,086View SEC Filing  
1/26/2018Roberto Pedro RosenkranzDirectorSell6,000$60.00$360,000.0029,000View SEC Filing  
1/22/2018Pat CotroneoCFOSell25,000$48.72$1,218,000.00208,852View SEC Filing  
1/22/2018Roberto Pedro RosenkranzDirectorSell71$50.00$3,550.0036,929View SEC Filing  
1/18/2018Kalevi KurkijarviDirectorSell6,000$47.38$284,280.0028,000View SEC Filing  
1/18/2018Thomas B NeffCEOSell18,900$47.64$900,396.002,981,447View SEC Filing  
1/5/2018Thomas B NeffCEOSell38,636$47.61$1,839,459.963,029,887View SEC Filing  
12/29/2017Thomas B NeffCEOSell38,636$48.39$1,869,596.04View SEC Filing  
12/28/2017Thomas B NeffCEOSell18,900$48.29$912,681.003,071,705View SEC Filing  
12/21/2017Thomas B NeffCEOSell38,636$44.66$1,725,483.763,022,934View SEC Filing  
12/18/2017Kalevi KurkijarviDirectorSell2,000$42.80$85,600.0022,000View SEC Filing  
12/14/2017K Peony YuInsiderSell2,851$43.70$124,588.70162,086View SEC Filing  
12/14/2017Thomas B NeffCEOSell18,900$42.71$807,219.003,060,887View SEC Filing  
12/12/2017Kalevi KurkijarviDirectorSell12,000$44.45$533,400.0036,000View SEC Filing  
12/11/2017Pat CotroneoVPSell2,851$46.00$131,146.00183,852View SEC Filing  
12/4/2017Gerald LemaDirectorBuy3,500$46.70$163,450.003,500View SEC Filing  
12/1/2017Jorma RouttiDirectorSell12,000$47.25$567,000.00133,840View SEC Filing  
11/17/2017Kalevi KurkijarviDirectorSell2,000$46.65$93,300.0024,000View SEC Filing  
11/16/2017Thomas B NeffCEOSell18,900$46.60$880,740.003,109,555View SEC Filing  
11/15/2017Thomas F Kearns JrDirectorSell18,000$45.22$813,960.00156,564View SEC Filing  
11/6/2017K Peony YuInsiderSell7,500$55.37$415,275.00170,104View SEC Filing  
10/31/2017Thomas B NeffCEOSell38,636$56.13$2,168,638.683,144,573View SEC Filing  
10/17/2017Kalevi KurkijarviDirectorSell2,000$52.24$104,480.0026,000View SEC Filing  
10/17/2017Thomas B NeffCEOSell38,636$55.02$2,125,752.723,176,861View SEC Filing  
10/16/2017Thomas B NeffCEOSell18,900$54.83$1,036,287.003,176,861View SEC Filing  
10/4/2017K Peony YuInsiderSell15,000$60.00$900,000.00View SEC Filing  
10/3/2017Thomas B NeffCEOSell38,636$55.09$2,128,457.24View SEC Filing  
10/2/2017K Peony YuInsiderSell40,000$54.63$2,185,200.00View SEC Filing  
10/2/2017Thomas B NeffCEOSell18,900$54.45$1,029,105.003,217,455View SEC Filing  
9/20/2017Thomas B NeffCEOSell38,636$53.46$2,065,480.563,246,754View SEC Filing  
9/18/2017Kalevi KurkijarviDirectorSell4,000$46.65$186,600.0030,000View SEC Filing  
9/14/2017K Peony YuInsiderSell2,851$51.00$145,401.00185,546View SEC Filing  
9/14/2017Thomas B NeffCEOSell38,636$51.67$1,996,322.123,297,655View SEC Filing  
9/13/2017Rory B RiggsDirectorSell25,000$51.92$1,298,000.00435,200View SEC Filing  
9/13/2017Thomas B NeffCEOSell18,900$51.29$969,381.003,297,655View SEC Filing  
9/11/2017Pat CotroneoVPSell2,851$49.45$140,981.95157,405View SEC Filing  
9/1/2017Jorma RouttiDirectorSell12,000$47.36$568,320.00133,840View SEC Filing  
8/29/2017Thomas B NeffCEOSell38,636$43.73$1,689,552.283,330,780View SEC Filing  
8/28/2017Thomas B NeffCEOSell18,900$43.04$813,456.003,330,780View SEC Filing  
8/21/2017K Peony YuInsiderSell7,500$41.03$307,725.00191,507View SEC Filing  
8/17/2017Kalevi KurkijarviDirectorSell2,000$40.74$81,480.0030,000View SEC Filing  
8/8/2017K Peony YuInsiderSell37,500$50.58$1,896,750.00236,507View SEC Filing  
8/8/2017Pat CotroneoVPSell95,000$50.61$4,807,950.00173,366View SEC Filing  
8/2/2017Pat CotroneoVPSell28,346$33.97$962,913.62170,666View SEC Filing  
8/1/2017K Peony YuInsiderSell10,000$33.48$334,800.00226,507View SEC Filing  
7/25/2017Thomas B NeffCEOSell38,636$35.09$1,355,737.243,330,780View SEC Filing  
7/24/2017Thomas B NeffCEOSell18,900$35.06$662,634.003,330,780View SEC Filing  
7/17/2017Kalevi KurkijarviDirectorSell2,000$33.45$66,900.0032,000View SEC Filing  
7/10/2017K Peony YuInsiderSell5,000$32.98$164,900.00216,507View SEC Filing  
7/7/2017Thomas B NeffCEOSell38,636$33.38$1,289,669.683,330,780View SEC Filing  
7/6/2017Pat CotroneoVPSell4,000$34.00$136,000.00167,366View SEC Filing  
7/6/2017Thomas B NeffCEOSell18,900$33.53$633,717.003,330,780View SEC Filing  
6/22/2017Pat CotroneoVPSell3,000$32.00$96,000.00166,366View SEC Filing  
6/22/2017Thomas B NeffCEOSell38,636$31.52$1,217,806.723,330,780View SEC Filing  
6/19/2017Pat CotroneoVPSell5,500$30.00$165,000.00168,866View SEC Filing  
6/16/2017Thomas B NeffCEOSell38,636$29.40$1,135,898.403,330,780View SEC Filing  
6/15/2017Kalevi KurkijarviDirectorSell2,000$28.50$57,000.0034,000View SEC Filing  
6/14/2017K Peony YuInsiderSell3,721$28.95$107,722.95221,507View SEC Filing  
6/12/2017Pat CotroneoVPSell2,891$28.75$83,116.25163,366View SEC Filing  
6/12/2017Toshinari TamuraDirectorSell30,000$28.89$866,700.0060,000View SEC Filing  
6/6/2017Thomas F Kearns JrDirectorSell18,000$28.71$516,780.00156,564View SEC Filing  
5/31/2017Thomas B NeffCEOSell38,636$26.21$1,012,649.563,345,941View SEC Filing  
5/16/2017Kalevi KurkijarviDirectorSell2,000$27.40$54,800.0036,000View SEC Filing  
5/16/2017Thomas B NeffCEOSell38,636$27.70$1,070,217.203,345,941View SEC Filing  
5/15/2017Thomas B NeffCEOSell18,900$27.75$524,475.003,345,941View SEC Filing  
5/10/2017K Peony YuInsiderSell5,000$26.38$131,900.00227,346View SEC Filing  
4/25/2017K Peony YuInsiderSell5,000$28.00$140,000.00236,046View SEC Filing  
4/25/2017Pat CotroneoVPSell6,500$28.00$182,000.00164,405View SEC Filing  
4/25/2017Thomas B NeffCEOSell38,636$26.92$1,040,081.123,345,941View SEC Filing  
4/24/2017Thomas B NeffCEOSell18,900$26.35$498,015.003,345,941View SEC Filing  
4/17/2017Kalevi KurkijarviDirectorSell2,000$25.25$50,500.0038,000View SEC Filing  
4/13/2017Thomas B NeffCEOSell38,636$24.79$957,786.443,345,941View SEC Filing  
4/4/2017Thomas B NeffCEOSell38,636$23.92$924,173.123,345,941View SEC Filing  
3/21/2017Thomas B NeffCEOSell38,636$24.34$940,400.243,345,941View SEC Filing  
3/20/2017Thomas B NeffCEOSell18,900$24.88$470,232.003,345,941View SEC Filing  
3/15/2017Thomas B NeffCEOSell38,636$25.07$968,604.523,353,983View SEC Filing  
2/16/2017Kalevi KurkijarviDirectorSell2,000$24.45$48,900.0040,000View SEC Filing  
2/14/2017Thomas B NeffCEOSell38,636$23.94$924,945.843,274,061View SEC Filing  
2/13/2017Thomas B NeffCEOSell18,900$23.97$453,033.003,274,061View SEC Filing  
2/9/2017Thomas B NeffCEOSell37,798$23.46$886,741.083,278,868View SEC Filing  
1/27/2017Thomas B NeffCEOSell37,798$23.29$880,315.423,288,484View SEC Filing  
1/19/2017Kalevi KurkijarviDirectorSell2,000$24.90$49,800.0042,000View SEC Filing  
1/12/2017Thomas B NeffCEOSell37,798$23.85$901,482.303,298,100View SEC Filing  
1/11/2017Pat CotroneoVPSell6,500$24.00$156,000.00138,748View SEC Filing  
1/10/2017K Peony YuInsiderSell5,000$23.56$117,800.00202,448View SEC Filing  
12/28/2016Thomas B NeffCEOSell37,798$20.74$783,930.523,307,718View SEC Filing  
12/16/2016Rory B RiggsDirectorSell20,000$20.87$417,400.00460,200View SEC Filing  
12/13/2016Thomas B NeffCEOSell37,798$21.24$802,829.523,317,334View SEC Filing  
12/12/2016Pat CotroneoVPSell2,344$22.05$51,685.20132,248View SEC Filing  
12/12/2016Thomas B NeffCEOSell18,899$21.48$405,950.523,317,334View SEC Filing  
11/29/2016Thomas B NeffCEOSell37,798$22.80$861,794.403,331,639View SEC Filing  
11/28/2016Thomas B NeffCEOSell18,899$22.74$429,763.263,331,639View SEC Filing  
11/18/2016Thomas F Kearns JrDirectorSell18,000$22.40$403,200.00165,564View SEC Filing  
11/17/2016Thomas B NeffCEOSell37,798$22.29$842,517.423,341,255View SEC Filing  
11/1/2016Thomas B NeffCEOSell37,798$16.76$633,494.483,350,871View SEC Filing  
10/19/2016Thomas B NeffCEOSell37,798$17.75$670,914.503,360,487View SEC Filing  
10/18/2016Thomas B NeffCEOSell18,899$17.94$339,048.063,360,487View SEC Filing  
10/4/2016Thomas B NeffCEOSell18,899$20.67$390,642.333,370,103View SEC Filing  
10/3/2016Thomas B NeffCEOSell18,899$20.55$388,374.453,370,103View SEC Filing  
9/21/2016Thomas B NeffCEOSell37,798$21.66$818,704.683,379,719View SEC Filing  
9/14/2016K Peony YuInsiderSell2,345$18.66$43,757.70206,502View SEC Filing  
9/12/2016Pat CotroneoVPSell2,345$18.22$42,725.90134,359View SEC Filing  
9/9/2016Thomas B NeffCEOSell37,798$18.99$717,784.023,389,335View SEC Filing  
8/26/2016Thomas B NeffCEOSell37,798$17.80$672,804.403,403,639View SEC Filing  
7/27/2016Thomas B NeffCEOSell37,798$18.38$694,727.243,413,255View SEC Filing  
7/13/2016Thomas B NeffCEOSell27,000$17.50$472,500.003,412,664View SEC Filing  
6/29/2016Thomas B NeffCEOSell27,000$16.02$432,540.003,439,764View SEC Filing  
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04138,114View SEC Filing  
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.003,466,664View SEC Filing  
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24210,257View SEC Filing  
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.003,507,164View SEC Filing  
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.003,526,053View SEC Filing  
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20141,868View SEC Filing  
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.003,552,353View SEC Filing  
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.003,579,353View SEC Filing  
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.003,579,353View SEC Filing  
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.003,606,353View SEC Filing  
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50115,434View SEC Filing  
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.003,633,453View SEC Filing  
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.003,667,175View SEC Filing  
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00115,133View SEC Filing  
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.003,596,207View SEC Filing  
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.003,596,207View SEC Filing  
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.5096,840View SEC Filing  
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.003,609,407View SEC Filing  
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.003,636,407View SEC Filing  
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76160,564View SEC Filing  
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.003,663,407View SEC Filing  
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00162,136View SEC Filing  
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.003,690,407View SEC Filing  
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.003,717,407View SEC Filing  
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28176,595View SEC Filing  
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.1455,614View SEC Filing  
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00178,345View SEC Filing  
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00107,775View SEC Filing  
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.003,746,689View SEC Filing  
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00169,936View SEC Filing  
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.003,746,689View SEC Filing  
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00169,936View SEC Filing  
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00183,345View SEC Filing  
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00187,904View SEC Filing  
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00187,904View SEC Filing  
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.0084,044View SEC Filing  
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.003,773,689View SEC Filing  
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00177,736View SEC Filing  
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.0084,044View SEC Filing  
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00192,904View SEC Filing  
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00197,904View SEC Filing  
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.003,800,689View SEC Filing  
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.003,827,689View SEC Filing  
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.0084,044View SEC Filing  
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.003,854,689View SEC Filing  
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35107,498View SEC Filing  
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00480,200View SEC Filing  
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.0012,000View SEC Filing  
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12202,904View SEC Filing  
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00107,251View SEC Filing  
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.003,862,751View SEC Filing  
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.003,866,782View SEC Filing  
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.0084,044View SEC Filing  
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

FibroGen (NASDAQ FGEN) News Headlines

Source:
DateHeadline
Fibrogen Makes A Strong Case As An Acquisition Target After Latest Lung Fibrosis DataFibrogen Makes A Strong Case As An Acquisition Target After Latest Lung Fibrosis Data
seekingalpha.com - May 22 at 9:03 AM
FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at ...FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at ...
www.globenewswire.com - May 21 at 4:37 PM
FibroGens pamrevlumab shows treatment effect in mid-stage IPF study; shares up 2% after hoursFibroGen's pamrevlumab shows treatment effect in mid-stage IPF study; shares up 2% after hours
seekingalpha.com - May 21 at 4:37 PM
FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018
finance.yahoo.com - May 21 at 4:37 PM
$28.28 Million in Sales Expected for FibroGen (FGEN) This Quarter$28.28 Million in Sales Expected for FibroGen (FGEN) This Quarter
www.americanbankingnews.com - May 19 at 3:58 AM
Kalevi Kurkijarvi Sells 4,000 Shares of FibroGen (FGEN) StockKalevi Kurkijarvi Sells 4,000 Shares of FibroGen (FGEN) Stock
www.americanbankingnews.com - May 18 at 8:21 PM
FibroGen (FGEN) CEO Sells $2,053,937.52 in StockFibroGen (FGEN) CEO Sells $2,053,937.52 in Stock
www.americanbankingnews.com - May 18 at 8:05 PM
-$0.58 EPS Expected for FibroGen (FGEN) This Quarter-$0.58 EPS Expected for FibroGen (FGEN) This Quarter
www.americanbankingnews.com - May 17 at 10:37 AM
FibroGen (FGEN) Given Consensus Recommendation of "Buy" by AnalystsFibroGen (FGEN) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 17 at 1:39 AM
FibroGen Upgraded By Mizuho On Continued R&D ProgressFibroGen Upgraded By Mizuho On Continued R&D Progress
finance.yahoo.com - May 16 at 9:25 AM
FibroGens (FGEN) "Buy" Rating Reaffirmed at MizuhoFibroGen's (FGEN) "Buy" Rating Reaffirmed at Mizuho
www.americanbankingnews.com - May 15 at 10:14 AM
Mizuho Securities Upgrades FibroGen (FGEN) to BuyMizuho Securities Upgrades FibroGen (FGEN) to Buy
www.streetinsider.com - May 15 at 9:39 AM
Zacks Investment Research Lowers FibroGen (FGEN) to SellZacks Investment Research Lowers FibroGen (FGEN) to Sell
www.americanbankingnews.com - May 15 at 12:00 AM
Q2 2018 Earnings Forecast for FibroGen (FGEN) Issued By Jefferies GroupQ2 2018 Earnings Forecast for FibroGen (FGEN) Issued By Jefferies Group
www.americanbankingnews.com - May 14 at 2:33 AM
FibroGen (FGEN) to Post Q2 2018 Earnings of ($0.56) Per Share, Leerink Swann ForecastsFibroGen (FGEN) to Post Q2 2018 Earnings of ($0.56) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 14 at 2:24 AM
FibroGen (FGEN) Director Sells $282,600.00 in StockFibroGen (FGEN) Director Sells $282,600.00 in Stock
www.americanbankingnews.com - May 11 at 8:01 PM
FibroGen (FGEN) Expected to Post FY2022 Earnings of $2.64 Per ShareFibroGen (FGEN) Expected to Post FY2022 Earnings of $2.64 Per Share
www.americanbankingnews.com - May 11 at 11:52 AM
BRIEF-FibroGen Reports Q1 Loss Per Share $0.50BRIEF-FibroGen Reports Q1 Loss Per Share $0.50
www.reuters.com - May 10 at 9:25 AM
Edited Transcript of FGEN earnings conference call or presentation 9-May-18 9:00pm GMTEdited Transcript of FGEN earnings conference call or presentation 9-May-18 9:00pm GMT
finance.yahoo.com - May 10 at 9:24 AM
FibroGen: 1Q Earnings SnapshotFibroGen: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 9:24 AM
FibroGen (FGEN) Issues Quarterly  Earnings ResultsFibroGen (FGEN) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 9:32 PM
FibroGen Reports First Quarter 2018 Financial ResultsFibroGen Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 4:44 PM
Thomas B. Neff Sells 39,636 Shares of FibroGen (FGEN) StockThomas B. Neff Sells 39,636 Shares of FibroGen (FGEN) Stock
www.americanbankingnews.com - May 4 at 7:33 PM
FibroGen (FGEN) Upgraded by Zacks Investment Research to HoldFibroGen (FGEN) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 4 at 1:56 PM
FibroGen (FGEN) Stock Rating Upgraded by ValuEngineFibroGen (FGEN) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 4 at 12:13 AM
FibroGen to Report First Quarter 2018 Financial Results on Wednesday, May 9, 2018FibroGen to Report First Quarter 2018 Financial Results on Wednesday, May 9, 2018
finance.yahoo.com - May 2 at 9:10 AM
FibroGen (FGEN) Expected to Post Quarterly Sales of $28.23 MillionFibroGen (FGEN) Expected to Post Quarterly Sales of $28.23 Million
www.americanbankingnews.com - May 1 at 2:02 AM
FibroGen (FGEN) to Release Earnings on MondayFibroGen (FGEN) to Release Earnings on Monday
www.americanbankingnews.com - April 30 at 7:23 AM
-$0.51 EPS Expected for FibroGen (FGEN) This Quarter-$0.51 EPS Expected for FibroGen (FGEN) This Quarter
www.americanbankingnews.com - April 29 at 9:08 PM
Consolidated Research: 2018 Summary Expectations for MGM Growth Properties, Reinsurance Group of America ...Consolidated Research: 2018 Summary Expectations for MGM Growth Properties, Reinsurance Group of America ...
globenewswire.com - April 27 at 9:43 AM
Form 4 FIBROGEN INC For: Apr 23 Filed by: Cotroneo PatForm 4 FIBROGEN INC For: Apr 23 Filed by: Cotroneo Pat
www.streetinsider.com - April 26 at 9:02 AM
BRIEF-Fibrogen Inc CEOs 2017 Compensation Was $7.1 MillionBRIEF-Fibrogen Inc CEO's 2017 Compensation Was $7.1 Million
www.reuters.com - April 24 at 4:53 PM
Form 4 FIBROGEN INC For: Apr 19 Filed by: Kurkijarvi KaleviForm 4 FIBROGEN INC For: Apr 19 Filed by: Kurkijarvi Kalevi
www.streetinsider.com - April 22 at 5:33 PM
FibroGen (FGEN) Receives Average Recommendation of "Hold" from AnalystsFibroGen (FGEN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 22 at 1:36 AM
Form 4 FIBROGEN INC For: Apr 19 Filed by: Rosenkranz Roberto PedroForm 4 FIBROGEN INC For: Apr 19 Filed by: Rosenkranz Roberto Pedro
www.streetinsider.com - April 21 at 9:04 AM
FibroGen (FGEN) Director Kalevi Kurkijarvi Sells 4,000 SharesFibroGen (FGEN) Director Kalevi Kurkijarvi Sells 4,000 Shares
www.americanbankingnews.com - April 20 at 7:40 PM
FibroGen (FGEN) CEO Thomas B. Neff Sells 39,636 SharesFibroGen (FGEN) CEO Thomas B. Neff Sells 39,636 Shares
www.americanbankingnews.com - April 19 at 10:10 PM
Form 4 FIBROGEN INC For: Apr 16 Filed by: Yu K PeonyForm 4 FIBROGEN INC For: Apr 16 Filed by: Yu K Peony
www.streetinsider.com - April 19 at 9:10 AM
Insider Selling: FibroGen (FGEN) Insider Sells 7,500 Shares of StockInsider Selling: FibroGen (FGEN) Insider Sells 7,500 Shares of Stock
www.americanbankingnews.com - April 18 at 7:28 PM
FibroGen (FGEN) Stock Rating Lowered by BidaskClubFibroGen (FGEN) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 10:53 PM
FibroGen (FGEN) Expected to Announce Quarterly Sales of $28.23 MillionFibroGen (FGEN) Expected to Announce Quarterly Sales of $28.23 Million
www.americanbankingnews.com - April 14 at 2:02 AM
 Brokerages Anticipate FibroGen (FGEN) Will Post Earnings of -$0.51 Per Share Brokerages Anticipate FibroGen (FGEN) Will Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - April 12 at 9:16 PM
FibroGen (FGEN) Rating Reiterated by Jefferies GroupFibroGen (FGEN) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 12 at 9:00 PM
Stifel Nicolaus Raises FibroGen (FGEN) Price Target to $80.00Stifel Nicolaus Raises FibroGen (FGEN) Price Target to $80.00
www.americanbankingnews.com - April 12 at 9:00 PM
FibroGen (FGEN) Director Sells $279,540.00 in StockFibroGen (FGEN) Director Sells $279,540.00 in Stock
www.americanbankingnews.com - April 11 at 10:37 PM
William Blair Reiterates Outperform Rating for FibroGen (FGEN)William Blair Reiterates Outperform Rating for FibroGen (FGEN)
www.americanbankingnews.com - April 11 at 6:13 PM
A Look at FibroGen’s Cash Flow Generating CapacityA Look at FibroGen’s Cash Flow Generating Capacity
finance.yahoo.com - April 9 at 9:25 AM
Understanding FibroGen’s Research PipelineUnderstanding FibroGen’s Research Pipeline
finance.yahoo.com - April 6 at 9:35 AM
FibroGens (FGEN) "Hold" Rating Reaffirmed at MizuhoFibroGen's (FGEN) "Hold" Rating Reaffirmed at Mizuho
www.americanbankingnews.com - March 31 at 8:16 PM
FibroGen (FGEN) Given Hold Rating at MizuhoFibroGen (FGEN) Given Hold Rating at Mizuho
www.americanbankingnews.com - March 29 at 5:16 PM

SEC Filings

FibroGen (NASDAQ:FGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

FibroGen (NASDAQ:FGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

FibroGen (NASDAQ FGEN) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.